Patents by Inventor Robert Yongxin Zhao
Robert Yongxin Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130266596Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: February 22, 2013Publication date: October 10, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Publication number: 20130011419Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: July 5, 2012Publication date: January 10, 2013Applicant: ImmunoGen, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Patent number: 8236319Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: April 30, 2009Date of Patent: August 7, 2012Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20120165537Abstract: Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.Type: ApplicationFiled: December 8, 2011Publication date: June 28, 2012Applicant: IMMUNOGEN, INC.Inventors: Wei LI, Robert Yongxin ZHAO
-
Patent number: 7906545Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: GrantFiled: July 17, 2009Date of Patent: March 15, 2011Assignee: Immunogen Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Publication number: 20110008373Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: ApplicationFiled: September 20, 2010Publication date: January 13, 2011Applicant: IMMUNOGEN, INC.Inventors: Robert Yongxin ZHAO, Ravi V.J. CHARI
-
Patent number: 7655660Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: GrantFiled: January 5, 2007Date of Patent: February 2, 2010Assignee: Immunogen Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Patent number: 7655661Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytotoxic drugs in a targeted fashion.Type: GrantFiled: June 23, 2008Date of Patent: February 2, 2010Assignee: ImmunoGen Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Publication number: 20090281158Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: ApplicationFiled: July 17, 2009Publication date: November 12, 2009Applicant: IMMUNOGEN, INC.Inventors: ROBERT YONGXIN ZHAO, Ravi V.J. Chari
-
Publication number: 20090274713Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: April 30, 2009Publication date: November 5, 2009Applicant: IMMUNOGEN INC.Inventors: Ravi V. J. CHARI, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20080260685Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytotoxic drugs in a targeted fashion.Type: ApplicationFiled: June 23, 2008Publication date: October 23, 2008Applicant: ImmunoGen Inc.Inventors: Robert Yongxin ZHAO, Ravi V.J. Chari
-
Patent number: 7388026Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: GrantFiled: September 2, 2005Date of Patent: June 17, 2008Assignee: Immunogen, Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Patent number: 7329760Abstract: Improved synthesis of seco(?)CBI (5-hydroxy-3-amino-1-[S]-(chloromethyl)-1,2-dihydro-3H-benz(e)indole): and improved syntheses therefrom of a wide variety of CC-1065 analogs that comprise a cyclopropabenzidole (CBI) alkylating moiety, and which are collectively DC1 and its derivatives, for the synthesis of cell-targeted therapeutic agents.Type: GrantFiled: October 7, 2002Date of Patent: February 12, 2008Assignee: Immunogen Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Patent number: 7049316Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: GrantFiled: October 27, 2003Date of Patent: May 23, 2006Assignee: Immunogen Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Patent number: 6756397Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: GrantFiled: April 5, 2002Date of Patent: June 29, 2004Assignee: Immunogen, Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari
-
Patent number: 6716821Abstract: Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via PEG linking groups, and methods for producing both are disclosed. A therapeutic composition comprising a therapeutically-effective amount of one of the cytotoxic conjugates of the present invention, and a method of killing selected cell populations comprising contacting target cells, or tissue containing target cells, with an effective amount of one of the cytotoxic conjugates, are also disclosed.Type: GrantFiled: December 21, 2001Date of Patent: April 6, 2004Assignee: Immunogen Inc.Inventors: Robert Yongxin Zhao, Michael Louis Miller, Wayne Charles Widdison, Ravi V. J. Chari
-
Publication number: 20040001838Abstract: Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via PEG linking groups, and methods for producing both are disclosed. A therapeutic composition comprising a therapeutically-effective amount of one of the cytotoxic conjugates of the present invention, and a method of killing selected cell populations comprising contacting target cells, or tissue containing target cells, with an effective amount of one of the cytotoxic conjugates, are also disclosed.Type: ApplicationFiled: December 21, 2001Publication date: January 1, 2004Applicant: ImmunoGen, Inc.Inventors: Robert Yongxin Zhao, Michael Louis Miller, Wayne Charles Widdison, Ravi V.J. Chari
-
Publication number: 20030199519Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: ApplicationFiled: April 5, 2002Publication date: October 23, 2003Applicant: IMMUNOGEN INC.Inventors: Robert Yongxin Zhao, Ravi V.J. Chari
-
Publication number: 20030195365Abstract: Improved synthesis of seco(−)CBI (5-hydroxy-3-amino-1-[S]-(chloromethyl)-1,2-dihydro-3H-benz(e)indole): 1Type: ApplicationFiled: October 7, 2002Publication date: October 16, 2003Applicant: IMMUNOGEN INC.Inventors: Robert Yongxin Zhao, Ravi V.J. Chari
-
Patent number: 6586618Abstract: Improved synthesis of seco(−)CBI (5-hydroxy-3-amino-1-[S]-(chloromethyl)-1,2-dihydro-3H-benz(e)indole): and improved syntheses therefrom of a wide variety of CC-1065 analogs that comprise a cyclopropabenzidole (CBI) alkylating moiety, and which are collectively DC1 and its derivatives, for the synthesis of cell-targeted therapeutic agents.Type: GrantFiled: October 7, 2002Date of Patent: July 1, 2003Assignee: Immunogen Inc.Inventors: Robert Yongxin Zhao, Ravi V. J. Chari